Dynavax Technologies (NASDAQ:DVAX) Upgraded to “Buy” at Wall Street Zen

Dynavax Technologies (NASDAQ:DVAX) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Other research analysts have also recently issued research reports about the stock. JMP Securities upped their target price on shares of Dynavax Technologies from $31.00 to $32.00 and gave the company a “market outperform” rating in a research report on Friday. The Goldman Sachs Group decreased their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.33.

Dynavax Technologies Trading Down 6.6%

NASDAQ DVAX opened at $10.33 on Friday. The firm’s 50-day moving average is $10.50 and its two-hundred day moving average is $11.56. Dynavax Technologies has a 12 month low of $9.22 and a 12 month high of $14.63. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84. The stock has a market capitalization of $1.24 billion, a P/E ratio of -22.46 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 4.87%. The company had revenue of $95.44 million for the quarter, compared to analysts’ expectations of $87.55 million. On average, sell-side analysts anticipate that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Trading of Dynavax Technologies

Several hedge funds have recently made changes to their positions in DVAX. Raymond James Financial Inc. acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth about $192,000. O Shaughnessy Asset Management LLC acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth about $131,000. Franklin Resources Inc. lifted its position in shares of Dynavax Technologies by 5.2% during the fourth quarter. Franklin Resources Inc. now owns 86,675 shares of the biopharmaceutical company’s stock worth $1,107,000 after purchasing an additional 4,260 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Dynavax Technologies by 20.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 2,796 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,169 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.